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Abstract. 
Small cell carcinoma (SmCC) of the prostate is a very rare and aggressive type of prostatic 
cancer. It is hard to early diagnose and most cases are diagnosed at advanced stage. The bones, 
liver, regional and distant lymph nodes are the most common sites of metastasis. The treatment 
for SmCC of the prostate is different from that of acinar adenocarcinoma. While chemotherapy 
is suggested, there is no standard regimen, let alone personalized strategy. Additionally, hor-
mone therapy does not often work for this type of prostate cancer. Here, we report a rare case of 
SmCC of the prostate who initially presented with lower cervical spine radiculopathy. 
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中文摘要 
  前列腺小細胞癌在臨床上罕見且不易早期診斷，過去統計上的發生率占前列腺癌約
1%，其病理特點為細胞較小，分化較低，PSA 可陰性，且多種神經內分泌標記物可陽性，
例如: chromogranin A 及 synaptophysin。其臨床症狀常以泌尿道排尿阻塞症狀表現，而實
驗室檢查較難有早期協助診斷的工具，臨床上常用的 PSA 可不升高。而因為發病年齡較
輕，故易誤診為慢性前列腺炎或前列腺肥大。而治療上早期以手術為主，但因不易早期
發現，故病人多只能接受化學治療併放射治療作疾病控制及症狀緩解，亦為治療效果不
彰的原因之一，我們在此提出一位前列腺小細胞癌的病例，病人臨床上以背痛及肢體麻
表現而無泌尿道相關症狀，在疾病初期亦不易確定診斷，之後接受化放療後，疾病控制
約十個月。藉由此個案提供臨床醫師相關治療經驗，並希望在未來能對此族群有更大規
模的研究及治療策略以改善治療成效。 
關鍵字: 小細胞癌、前列腺、脊椎轉移 
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INTRODUCTION 
Extrapulmonary small cell carcinomas are ex-
tremely rare entities and they account for approxi-
mately 2.5 to 5% of all small cell carcinomas (SmCC) 
in the United States [1,2]. Among them, approximate-
ly 10% of cases occur in the prostate which was first 
described by Wenk et al. [3]. The disorder is distinct 
from the far more common prostatic adenocarcinomas, 
and it is characterized by earlier onset and more ag-
gressive behavior [4]. The serum levels of the prostate 
specific antigen (PSA) in SmCC do not correlate with 
disease activity and are not useful for posttreatment 
surveillance as in prostate adenocarcinoma [5]. We 
report on a rare case of SmCC of the prostate who 
initially presented with lower cervical spine radicu-
lopathy.  
 
CASE REPORT  
A 53-year-old man presented to the emergency 
department with chronic progressive persistent dull 
backache. He had also experienced numbness without 
loss of strength in his right upper arm for three weeks. 
He denied any previous medical or traumatic history. 
His vital signs were within normal limits on admission. 
Physical examination disclosed insignificant abnor-
malities and muscle strength was 5/5 in all four limbs. 
Sensory deficit in a dermatomal distribution of T1 was 
observed, and digital rectal exam (DRE) did not show 
nodules, asymmetry or induration of the prostate.  
The plain radiographs of the cervical and thora-
columbar spine showed small osteophyte formation of 
cervical vertebral bodies and mild degenerative 
change with marginal spurs formation of the thora-
columbar spine. Electromyography and nerve conduc-
tion studies showed insignificant results. Magnetic 
resonance imaging (MRI) of the cervical spine 
showed numerous small, similar-appearing hypodense 
lesions distributed throughout the cervical and thorac-
ic bodies. Tumor impingement upon the right T1/2 
foramen was also noted (Figure 1).  
Laboratory studies showed an elevated carci-
noembryonic antigen (CEA) level (7.26 ng/ml, normal 
0.0-5.0 ng/ml), carbohydrate antigen 19-9 level (111.4 
unit/ml, normal 1.0-35.0 unit/ml) and a normal PSA 
level (1.41 ng/ml, normal 0-3 ng/ml). The total white 
blood cell count was 6,300/μl (normal 4,000-11,000/ 
μl), hemoglobin was 13.2 g/dl (13.5–17.0 g/dl), and 
platelet count was 201,000/μl (150,000–400,000/μl). 
Computed tomography (CT) scan of the abdomen 
revealed several nodules near the left pararectal and 
iliac vessel areas, and the largest nodule was 2.4 x 1.3 
cm in size in the left pararectal area. Colonoscopy 
showed a 2 cm mass in the ascending colon, which 
was pathologically proven to be an adenoma. 
Under the impression of malignancy with T-spine 
involvement, the patient received whole body positron 
emission tomography (PET)/CT scan and intense 
18F-fluorodeoxyglucose (18F-FDG) uptake over the 
cervical, thoracic, lumbar spines, sacrum, rib cages, 
pelvis, right femur, right ascending colon and prostate 
was seen (Figure 2). 
Transrectal ultrasound-guided needle biopsy of 
prostate showed SmCC Gleason grade 5+5. Immuno-
histochemical staining was negative for PSA, positive 
for cytokeratin 18, chromogranin A (CgA), synapto-
physin (Syn), and thyroid transcription factor-1 
(TTF-1), and focally positive for neuron-specific eno-
lase (NSE) (Figure 3). 
Under the diagnosis of poor differentiated neuro-
endocrine SmCC of the prostate, cT2cN1M1c, stage 
IV the patient received six cycles of triweekly intra-
venous etoposide 80 mg/m2 (on day 1) and cisplatin 
80 mg/m2 (daily on days 1 through 3). Palliative radi-
otherapy was given with 30 Gy in 10 fractions for 
bony metastasis. After the sixth cycle, follow-up MRI  
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Figure 1. MRI of the cervical spine revealed numerous small, similar-appearing hypodense lesions dis-
tributed throughout the cervical and thoracic bodies. Tumor impingement upon the right T1/2 
foramen is seen (arrow) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Whole body PET/CT scan showed intense 18F-FDG uptake in the entire skeleton, including 
cervical, thoracic, lumbar spines, sacrum, rib cages, pelvis, and right femur (A); Unusually 
high FDG uptake was found in the right abdomen with several focal intense FDG activity lo-
calized in the right ascending colon (B) and prostate region (C) 
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Figure 3. Transrectal ultrasound-guided needle biopsy of prostate showed (A) Tumor cells characterized by hy-
perchromatic nuclei, a very high N/C ratio, fine granular chromatin and inconspicuous nucleoli infil-
trating the stroma. (Hematoxylin-Eosin stain ×200). Immunohistochemical staining was negative for 
PSA (B), positive for chromogranin A staining (C), and positive for cytokeratin 18 in membrane and 
dot-like patterns (D) 
 
 
showed stable disease, but he succumbed to profound 
septic shock 4 months later, 10 months after the date 
of his initial diagnosis. 
 
DISCUSSION 
Prostate SmCC is a poorly differentiated tumor 
with a very low incidence, accounting for less than 2% 
of all prostate cancers [6,7]. SmCC has an aggressive 
character and easily metastasizes to the liver, bones, 
bladder, rectum, central nervous system and lungs [8]. 
Unlike patients with prostate adenocarcinoma, most 
patients with SmCC of the prostate are symptomatic at 
diagnosis. Signs and symptoms, in order of frequency, 
include obstructive, neurologic, and constitutional 
symptoms, followed by symptoms from parane-
oplastic syndromes, bone pain, hydronephrosis, ab-
dominal pain, hematochezia, and hematuria [9]. 
However, it is sometimes difficult to detect early 
due to negative DRE and disproportionately low PSA 
levels in the presence of metastatic disease. A com-
plete physical examination and laboratory studies 
should be performed due to the risk of paraneoplastic 
syndromes, including Cushing's syndrome, peripheral 
neuropathy, membranous nephropathy, and hyper-
calcemia without bone metastases [10]. 
SmCC of the prostate usually stains positive for 
NSE, synaptophysin and chromogranin A, and nega-
tive for androgen receptor and PSA [11]. TTF-1 can 
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be positive in up to half of small cell carcinomas and 
is not found in the poorly diffrentiated adenocarcino-
mas [12,13]. TTF-1 is a tissue specific transcription 
factor expressed in epithelial cells of the thyroid and 
lung as well as in certain areas of the brain [14]. 
SmCC of the prostate can be distinguished from me-
tastasis from the lung based on immunohistochemical 
staining for NSE, synaptophysin, and chromogranin A, 
ERG rearrangement (positive in 50% of cells) or 
MYC amplification (positive in 50% of cells) in ge-
netic studies [15-17]. 
Interestingly, our case presented with backache 
and limb numbness rather than obstructive urinary 
symptoms. In addition, constitutional symptoms such 
as body weight loss or poor appetite were not ob-
served. The negative DRE and normal serum PSA 
level increased the difficulty of early detection.  
To date, no standard chemotherapy regimen has 
been formally acknowledged for SmCC of the prostate 
due to the small number of cases [6]. Surgery is rec-
ommended for early lesions and chemotherapy is the 
main strategy in metastatic disease with radiation for 
local control [5,18,19]. Because most SmCC cases are 
already in advanced stage when diagnosed, poor 
prognosis is expected. In practice, chemotherapy 
regimens for SmCC of the lung are typically used to 
treat the origin of prostate. It has been reported that 
the combined use of etoposide/cisplatin (EP) had an 
efficacy of around 61% in SmCC of the prostate [20]. 
Recent studies reported that the median survival time 
ranged from 5 to 17.5 months [5,20-22]. Additionally, 
SmCC is a hormone-independent tumor, and androgen 
deprivation therapy is not effective for SmCC [23]. 
Neuroendocrine diffrentiation may also play an im-
portant role in the development of androgen resistance 
and may limit responsiveness to androgen signalling 
inhibition [19,24,25]. Our case received the EP regi-
men and overall survival was 10 months. The initial 
purposes of radiotherapy are symptom control and 
palliation. In younger patients, more aggressive radi-
otherapy strategies may be considered due to radio-
sensitivity of SmCC of the prostate [26]. 
In conclusion, SmCC of the prostate is a rare, ag-
gressive disease with poor prognosis and is not asso-
ciated with elevated serum PSA. Further studies 
should be undertaken to determine the appropriate 
treatment protocols for patients with SmCC of the 
prostate. 
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